KEY POINTS
- This multicenter, open-label randomized clinical trial (NCT04823468) was conducted at six Chinese tertiary hospitals between July 2021 and May 2025. A total of 236 patients were randomized, and 216 were included in the prespecified modified intention-to-treat population. Eligible participants were aged 18–70 years, had newly diagnosed stage II–IVA nasopharyngeal carcinoma, planned concurrent chemoradiotherapy, and a baseline Patient-Generated Subjective Global Assessment score of 0–8, excluding patients with substantial pre-existing nutritional compromise requiring immediate intervention.
- Patients were randomized 1:1 to early or routine oral nutritional supplementation. The early group began oral nutritional supplements at the start of concurrent chemoradiotherapy, whereas the routine group began supplementation after predefined nutritional deterioration. The principal question was whether proactive nutritional intervention could prevent clinically meaningful treatment-associated weight loss rather than waiting until nutritional decline had already developed.
- The primary endpoint significantly favored early nutritional supplementation. Weight loss exceeding 5% of baseline body weight occurred in 70/107 patients (65.4%) receiving early supplementation versus 88/109 (80.7%) receiving routine supplementation. The relative risk was 0.81 (95% CI 0.68–0.96; p=0.01), corresponding to an absolute reduction of 15.3 percentage points. An intention-to-treat analysis including all randomized participants showed a consistent result (RR 0.78, 95% CI 0.65–0.93).
- Severe radiation-induced oral mucositis was less frequent with early supplementation. Grade ≥3 mucositis occurred in 15/107 patients (14.0%) in the early group compared with 29/109 (26.6%) in the routine group, corresponding to RR 0.53 (95% CI 0.30–0.93). This was a secondary finding and should be interpreted in the context of the study's open-label design and multiple outcomes rather than as definitive evidence that nutritional supplementation directly prevents mucosal injury.
- Exploratory economic analysis suggested similar short-term costs with slightly higher utility. Reported best-case costs were US$9,560.56 with early supplementation versus US$9,685.23 with routine supplementation. Corresponding quality-adjusted life-years were 0.1144 versus 0.1132. These differences suggest potentially favorable short-term cost utility, but the available report does not establish long-term economic benefit or generalizability to other healthcare systems.
- The available article extract does not provide detailed treatment-dose, adherence, or longer-term outcome data. Although secondary endpoints included nutritional status, quality of life, and radiotherapy interruptions, the supplied abstract does not report numerical findings for these outcomes. Consequently, no conclusions can be drawn from the available material regarding RT completion, hospitalization, feeding-tube use, long-term nutritional recovery, or survival. Longer-term comparative assessment is required to determine whether reduced acute weight loss translates into more durable clinical benefit.
CLINICAL TAKEAWAY
Starting oral nutritional supplementation at the beginning of concurrent chemoradiotherapy significantly reduced clinically meaningful weight loss in patients with nasopharyngeal carcinoma compared with supplementation initiated after nutritional deterioration. The randomized findings support proactive nutritional assessment and early intervention, with an additional encouraging signal for severe oral mucositis. Longer-term outcomes, intervention adherence, and cost-effectiveness across different clinical settings require further evaluation.